What can 70,000+ human and chimpanzee regulatory elements tell us about skeletal evolution? A new study in @genomebiolevol.bsky.social uncovered genomic differences linked to skeletal development using a massively parallel reporter assay. We're glad our ATx® could support! 🔗 https://bit.ly/3PV2naf

Wondering where the ExPERT DTx™ fits within the broader ExPERT platform? Here, in a Cell & Gene webinar, Dr. Grace Tharmarajah explains how workflows developed on the DTx™ can translate across the platform, supporting a smoother path from discovery to process development. 🔗https://bit.ly/49AoWI3

On Tuesday, MaxCyte CEO Maher Masoud sat down with Big4Bio for a wide-ranging conversation on the state of the industry, his journey to MaxCyte, and our “obsession with customer success.” 🌟 Read it in full ➡️ ttps://bit.ly/4f9mITM

Still time to join tomorrow’s webinar with Grace Tharmarajah on scalable, reproducible high-throughput electroporation for cell therapy workflows. She’ll also introduce the new ExPERT DTx™, processing up to 96 samples in under 3 minutes. 📅 May 21 | 1pm ET 🔗 https://bit.ly/3PhBIEf

Great conversations at PEGS Boston last week around biologics discovery challenges. One theme we heard often: balancing throughput with reproducibility in screening workflows. Thanks to everyone who stopped by to see the ExPERT DTx™ and GTx®. What’s been hardest to scale in your workflows lately?

High-throughput workflows often force teams to choose between speed and flexibility. Next week, Grace Tharmarajah joins Cell & Gene to discuss how the ExPERT DTx™ supports scalable, reproducible non-viral CAR-T optimization. How are you approaching this challenge? Register: https://bit.ly/3PhBIEf

It's day 2 of ISCT, International Society for Cell & Gene Therapy in Dublin, which means the return of the green sample! 🇮🇪 👋 Stop by booth 2904, say hi to Ben Cavagan and Linda Meggiolaro, and check out the ExPERT GTx® and DTx™ in action.

“This is just the beginning.” In a new GEN article, our CEO Maher Masoud highlights progress in CRISPR (first approvals, allogeneic momentum) while noting key barriers like complex conditioning. For Masoud, success means simpler, scalable therapies that reach more patients.🔗 https://bit.ly/4d3xKqC

Our CEO Maher Masoud sat down with @pharmexec.bsky.social to discuss what it takes to scale cell and gene therapies. One point that stood out: avoiding constant re-optimization when moving from R&D to commercial. Curious, how are other teams handling that transition? 👀 https://bit.ly/4cT8pzE

We’re celebrating International Day of Immunology! 🎈 Regulatory T cells (this year's theme) are all about balance. In practice, working with primary immune cells rarely feels that way. If you’re working with immune cells, what’s been hardest to keep consistent? #DayOfImmunology

Hi Bluesky 👋 At MaxCyte, we work with teams engineering the next generation of cell therapies from discovery to clinic by offering: • Scalable platforms • Thoughtful risk assessment • Real partnership Curious, what’s been most challenging in getting cell therapies closer to the clinic?